← 홈

Antibody · 혈액암 (AML/ALL)

286개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 286개
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Oleclumab)

Stage III Non-small Cell Lung Cancer; Unresectable · Stage III Non-small Cell Lung Cancer

#StageIIINon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 23.9%임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

durvalumab (Imfinzi, Durvalumab + SoC chemotherapy)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase3#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Tremelimumab + RT)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + doxorubicin + ifosfamide)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab Anlotinib Carboplatin Nab-paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab plus radiotherapy)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib)

Lung Cancer; Small Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

8 / 15 페이지

← 이전다음 →